Darunavir

Drug Profile

Darunavir

Alternative Names: Prezista; TMC-114; Virem

Latest Information Update: 12 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections; HIV-1 infections

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Feb 2017 Janssen completes a phase III trial in HIV-1 infections (Combination therapy, Treatment-experienced, Monotherapy) in Cameroon, Burkina Faso, Senegal (PO) (NCT01905059)
  • 18 Jul 2016 The US FDA approves use of darunavir in pregnant women with HIV-1 infections
  • 18 Jul 2016 Adverse events data from a phase III trial in HIV-1 infections released by Janssen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top